Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: Biochemical mechanisms

Journal of the American Society of Nephrology

Volumn 13, Issue 10, 2002, Pages 2478-2487

  Miyata, Toshio ^a   Van Ypersele De Strihou, Charles ^a   Ueda, Yasuhiko ^a   Ichimori, Kohji ^a   Inagi, Reiko ^a   Onogi, Hiroshi ^a   Ishikawa, Naoyoshi ^a   Nangaku, Masaomi ^a   Kurokawa, Kiyoshi ^a  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1H TETRAZOLE; 2 ISOPROPYLIDENEHYDRAZONO 4 OXO 5 THIAZOLIDINYLACETANILIDE; 5 (4' METHYLBIPHENYL 2 YL) 1H TETRAZOLE; 5 PHENYL 1H TETRAZOLE; 6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT; AMINOGUANIDINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRILAT; IRBESARTAN; LOSARTAN; NIFEDIPINE; OLMESARTAN; PENTOSIDINE; PERINDOPRILAT; PYRIDOXAMINE; TELMISARTAN; TEMOCAPRILAT; TETRAZOLE DERIVATIVE; UNCLASSIFIED DRUG; VALSARTAN;

AEROBIC METABOLISM; ARTICLE; BIOCHEMISTRY; CHELATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG TOLERABILITY; HUMAN; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN SYNTHESIS;

EID: 0036786046     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ASN.0000032418.67267.F2     Document Type: Article

References (53)

1. Brownlee M, Cerami A, Vlassara H: Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 318: 1315-1321, 1988
2. Palinski W, Koschinsky T, Butler SW, Miller E, Vlassara H, Cerami A, Witztum JL: Immunological evidence for the presence of advanced glycosylation end products in atherosclerotic lesions of euglycemic rabbits. Arterioscler Thromb Vasc Biol 15: 571-582, 1995
3. Palinski W, Miller E, Witztum JL: Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc Natl Acad Sci USA 92: 821-825, 1995
4. Anderson MM, Hazen SL, Hsu FF, Heinecke JW: Human neutrophils employ the myeloperoxidase-hydrogen peroxide-chloride system to convert hydroxy-amino acids into glycolaldehyde, 2-hydroxypropanol, and acrolein: A mechanism for the generation of highly reactive α-hydroxy and α, β-unsaturated aldehydes by phagocytes at sites of inflammation. J Clin Invest 99: 424-432, 1997
5. ε-(carboxymethyl)lysine on proteins: a mechanism for producing advanced glycation end products at sites of inflammation. J Clin Invest 104: 103-113, 1999
6. Kirstein M, Brett J, Radoff S, Ogawa S, Stern D, Vlassara H: Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: Role in vascular disease of diabetes and aging. Proc Natl Acad Sci USA 87: 9010-9014, 1990
7. Sell DR, Lapolla A, Odetti P, Forgarty J, Monnier VM: Pentosidine formation in skin correlates with severity of complication in individuals with long standing IDDM. Diabetes 41: 1286-1292, 1992
8. McCance DR, Dyer DG, Dunn JA, Bailie KE, Thorpe SR, Baynes JW, Lyons TJ: Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. J Clin Invest 91: 2470-2478, 1993
9. Beisswenger PJ, Moore LL, Brink-Johnsen T: Increased collagen-linked pentosidine levels and advanced glycosylation end products in early diabetic nephropathy. J Clin Invest 92: 212-217, 1993
10. Sugiyama S, Miyata T, Ueda Y, Tanaka H, Maeda K, Kawashima S, van Ypersele de Strihou C, Kurokawa K: Plasma level of pentosidine, an advanced glycation end product, in diabetic patients. J Am Soc Nephrol 9: 1681-1688, 1998
11. 2-Microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis: J Clin Invest 92: 1243-1252, 1993
12. 2microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway. J Clin Invest 98: 1088-1094, 1996
13. Miyata T, van Ypersele de Strihou C, Kurokawa K, Baynes JW: Alterations in non-enzymatic biochemistry in uremia: Origin and significance of "carbonyl stress" in long-term uremic complications. Kidney Int 55: 389-399, 1999
14. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A: Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 232: 1629-1632, 1986
15. Nakamura S, Makita Z, Ishikawa S, Yasumura K, Fujii W, Yanagisawa K, Kawata T Koike T: Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation. Diabetes 46: 895-899, 1997
16. Sell DR, Monnier VM: Structure elucidation of a senescence cross-link from human extracellular matrix. J Biol Chem 264: 21597-21602, 1989
17. ε-carboxymethyllysine as a degradation product of fructoselysine in glycated protein. J Biol Chem 261: 4889-4894, 1986
18. Esterbauer H, Schuer RJ, Zollner H: Chemistry and biochemistry of 4-hydroxynonenal, malondialdehyde and related aldehyde. Free Radic Biol Med 11: 81-128, 1991
19. Miyata T, Ueda Y, Asahi K, Izuhara Y, Inagi R, Saito A, van Ypersele de Strihou C, Kurokawa K: Mechanism of the inhibitory effect of OPB-9195 [(±)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-ylacetanilide] on advanced glycation end product and advanced lipoxidation end product formation. J Am Soc Nephrol 11: 1719-1725, 2000
20. Miyata T, Ueda Y, Yamada Y, Saito A, Jadoul M, van Ypersele de Strihou C, Kurokawa K: Carbonyl stress in uremia: Accumulation of carbonyls accelerate the formation of pentosidine, an advanced glycation end product. J Am Soc Nephrol 9: 2349-2356, 1998
21. crc. Cell Biochem 72: 1-7, 1999
22. Soulis-Liparota T, Cooper M, Papazoglou D, Clarke B, Jerums G: Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 40: 1328-1334, 1991
23. Miyata T, Ishikawa S, Asahi K, Inagi R, Suzuki D, Horie K, Tatsumi K, Kurokawa K: 2-Isopropylidenehydrazono-4-oxothiazolidin-5ylacetanilide (OPB-9195) inhibits the neointima proliferation of rat carotid artery following balloon injury: Role of glycoxidation and lipoxidation reactions in vascular tissue damage. FEBS Lett 445: 202-206, 1999
24. Taguchi T, Sugiura M, Hamada Y, Miwa I: In vivo formation of a Schiff base of aminoguanidine with pyridoxal phosphate. Biochem Pharmacol 55: 1667-1671, 1998
25. Mizuno M, Sada T, Ikeda M, Fukuda N, Miyamoto M, Yanagisawa H, Koike H: Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist. Eur J Pharmacol 285: 181-188, 1995
26. 2-microglobulin-containing amyloid fibrils in patients with dialysis-related amyloidosis. Proc Natl Acad Sci USA 93: 2353-2358, 1996
27. ε-(carboxymethyl)hydroxylysine in human skin collagen. Biochemistry 30: 1205-1210, 1991
28. Miyata T, Horie K, Ueda Y, Fujita Y, Izuhara Y, Hirano H, Uchida K, Saito A, van Ypersele de Strihou C, Kurokawa K: Advanced glycation and lipidoxidation of the peritoneal membrane: Respective roles of serum and peritoneal fluid reactive carbonyl compounds. Kidney Int 58: 425-435, 2000
29. Asahi K, Ichimori K, Nakazawa H, Izuhara Y, Inagi R, Watanabe T, Miyata T, Kurokawa K: Nitric oxide inhibits the formation of advanced glycation end products. Kidney Int 58: 1780-1787, 2000
30. Price DL, Rhett PM, Thorpe SR, Baynes JW: Chelating activity of advanced glycation end-product (AGE) inhibitors. J Biol Chem 276: 48967-48972, 2001
31. Booth AA, Khalifah RG, Todd P, Hudson BG: In vitro kinetic studies of formation of antigenic advanced glycation end products (AGEs): Novel inhibition of post-Amadori glycation pathways. J Biol Chem 272: 5430-5437, 1997
32. Monnier VM, Transition metals redox: Reviving an old plot for diabetic vascular disease. J Clin Invest 107: 799-801, 2001
33. Glomb MA, Monnier VM: Mechanism of protein modification by glyoxal and glycoaldehyde, reactive intermediates of the Maillard reaction. J Biol Chem 270: 10017-10026, 1995
34. Thornalley PJ: Advanced glycation and development of diabetic complications: Unifying the involvement of glucose, methylglyoxal and oxidative stress. Endocrinol Metab 3: 149-166, 1996
35. Wells-Knecht KJ, Zyzak DV, Litchfield JE, Thorpe SR, Baynes JW: Mechanism of autoxidative glycosylation: Identification of glyoxal and arabinose as intermediates in the autoxidative modification of proteins by glucose. Biochemistry. 34: 3702-3709, 1995
36. Hayashi T, Namiki M: Role of sugar fragmentation in the Maillard reaction. In: Amino-Carbonyl Reaction in Food and Biological Systems, edited by Fujimaki M, Namiki M, Kato H, Amsterdam, Elsevier Press, 1986, pp 29-38
37. Miyata T, Kurokawa K, van Ypersele de Strihou C: Advanced glycation and lipoxidation end products: Role of reactive carbonyl compounds generated during carbohydrate and lipid metabolism. J Am Soc Nephrol 11: 1744-1752, 2000
38. Wolff SP, Jiang ZY, Hunt JV: Protein glycation and oxidative stress in diabetes mellitus and ageing. Free Radic Biol Med 10: 339-352, 1991
39. Baynes JW: Role of oxidative stress in development of complications in diabetes. Diabetes 40: 405-412, 1991
40. Khalifah RG, Bayne JW, Hudson BG: Amadorins: Novel post-Amadori inhibitors of advanced glycation reactions. Biochem Biophys Res Commun 257: 251-258, 1999
41. Degenhardt TP, Alderson NL, Arrington DD, Beattie RJ, Basgen JM, Steffes MW, Thorpe SR, Baynes JW: Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 61: 939-950, 2002
42. Kilhovd BK, Hjerkinn EM, Seljeflot I, Berg TJ, Reikvam AA: The ACE inhibitor ramipril influences the serum levels of advanced glycation endproducts in high risk patients with coronary artery disease: Results from a HOPE substudy (abstract). Eur Heart J 22: 27, 2001
43. Sebekova K, Schinzel R, Munch G, Krivosikova Z, Dzurik R, Heidland A: Advanced glycation end-product levels in subtotally nephrectomized rats: Beneficial effects of angiotensin II receptor 1 antagonist losartan. Milzer Electrolyte Metab 25: 380-383, 1999
44. Bauer JH, Reams GP, Hewett J, Klachko D, Lau A, Messina C, Knaus V: A randomized, double-blind, placebo-controlled trial to evaluate the effect of enalapril in patients with clinical diabetic nephropathy. Am J Kidney Dis 20: 443-457, 1992
45. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 329: 1456-1462, 1993
46. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I: Renoprotective effect of the angiotensin II receptor antagonist Irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851-860, 2001
47. Heart outcomes prevention evaluation (HOPE) study investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet 355: 253-259, 2000
48. Pitt B, Poole-Wilson PA, Seoul R, Martinez FA, Dickstein K, Camon AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D, Thiyagarajan B: Effects of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trail-The losartan heart failure survival study ELITE II. Lancet 355: 1582-1587, 2000
49. Heinecke JW: Oxidants and antioxidants in the pathogenesis of atherosclerosis: Implications for the oxidized low density lipoprotein hypothesis. Atherosclerosis. 141: 1-15, 1998
50. Miyata T, Devuyst O, Kurokawa K, van Ypersele de Strihou C: Towards better dialysis compatibility: Advances in the biochemistry and pathophysiology of the peritoneal membrane. Kidney Int 61: 375-386, 2002
51. Onozato ML, Tojo A, Goto A, Fujita T, Wilcox CS: Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: Effects of ACEI and ARB. Kidney Int 61: 186-194, 2002
52. Pennathur S, Wagner JD, Leeuwenburgh C, Litwak KN, Heinecke JW: A hydroxyl radical-like species oxidizes cynomolgus monkey artery wall proteins in early diabetic vascular disease. J Clin Invest 107: 853-860, 2001
53. Saxena P, Saxena AK, Cui X-L: Obrenovich, M., Gudipaty K, Monnier, VM: Transition metal-catalized oxidation of ascorbate in human cataract extracts: Possible role of advanced glycation end products. Invest Ophthalmol Vis Sci 41: 1473-1481, 2000